Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Vet Microbiol ; 121(1-2): 94-104, 2007 Mar 31.
Artículo en Inglés | MEDLINE | ID: mdl-17187945

RESUMEN

Experimental groups of 15 susceptible 3-week-old turkeys were inoculated oculonasally with avian metapneumovirus (APV) subtype A and susceptible Escherichia coli O2:K1 and Ornithobacterium rhinotracheale (ORT) bacteria, with a 3 days interval between viral and bacterial inoculation and approximately 8h between the two bacterial inoculations. The aims of the present study were to assess the efficacy of drinking-water administration of enrofloxacin for 3 and 5 days, amoxicillin for 5 days and florfenicol for 5 days for the treatment of the resulting respiratory disease, based on clinical and bacteriological examinations. Antimicrobial treatment started 1 day after dual bacterial inoculation. After infection, the birds were examined and scored for clinical signs daily, weighed at different times, and their tracheae swabbed daily. Five birds were euthanised and examined for macroscopic lesions at necropsy at 5 days post-bacterial inoculation (dpbi) and the remainder at 15dpbi. Samples of the turbinates, trachea, lungs, sinuses, air sacs, heart, pericardium and liver were collected for bacteriological examination. Recovery from respiratory disease caused by an APV/E. coli/ORT triple infection in 3-week-old turkey poults was overall most successful after enrofloxacin treatment, irrespective of treatment duration, followed by florfenicol treatment. Compared with the untreated group, clinical signs as well as ORT and E. coli multiplication in the respiratory tract were significantly reduced by both enrofloxacin treatments and the florfenicol treatment, with the enrofloxacin treatments showing significantly better reductions than the florfenicol treatment. Five-day treatment with amoxicillin, compared with the untreated group, did not cause a significant reduction in any of the aforementioned parameters.


Asunto(s)
Antibacterianos/uso terapéutico , Infecciones por Escherichia coli/veterinaria , Infecciones por Paramyxoviridae/veterinaria , Enfermedades de las Aves de Corral/tratamiento farmacológico , Enfermedades de las Aves de Corral/microbiología , Enfermedades Respiratorias/veterinaria , Pavos , Amoxicilina/uso terapéutico , Animales , Área Bajo la Curva , Peso Corporal/efectos de los fármacos , Enrofloxacina , Escherichia coli/crecimiento & desarrollo , Infecciones por Escherichia coli/complicaciones , Infecciones por Escherichia coli/tratamiento farmacológico , Infecciones por Escherichia coli/microbiología , Infecciones por Flavobacteriaceae/complicaciones , Infecciones por Flavobacteriaceae/tratamiento farmacológico , Infecciones por Flavobacteriaceae/microbiología , Infecciones por Flavobacteriaceae/veterinaria , Fluoroquinolonas/uso terapéutico , Metapneumovirus/crecimiento & desarrollo , Pruebas de Sensibilidad Microbiana/veterinaria , Ornithobacterium/crecimiento & desarrollo , Infecciones por Paramyxoviridae/complicaciones , Infecciones por Paramyxoviridae/tratamiento farmacológico , Infecciones por Paramyxoviridae/virología , Enfermedades de las Aves de Corral/virología , Enfermedades Respiratorias/tratamiento farmacológico , Enfermedades Respiratorias/microbiología , Enfermedades Respiratorias/virología , Organismos Libres de Patógenos Específicos , Tianfenicol/análogos & derivados , Tianfenicol/uso terapéutico , Tráquea/microbiología , Tráquea/virología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA